*Last updated July 28, 2023.
After months of preparation and close collaboration with patient advocacy groups, patients and carers, the T2EVOLVE and QUALITOP consortia are proud to launch their European patient survey on CAR T-cell therapy.
This survey will help to understand patients’ experiences with CAR T-cell therapy, evaluate the impact of this treatment on quality of life and identify unmet needs. With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.
All European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.
Now, we need you!
If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!
If you are not a patient but you are in close contact with patients who receive CAR T-cell therapy (e.g. a patient association, hematologist, nurse or other healthcare professional) we would like to invite you to help us by sharing this survey with patients! 🖨️
The survey is available in English, French, German, Spanish, Italian, Portuguese and Dutch.
2 WAYS TO ACCESS AND SHARE THE SURVEY
(BEFORE October 31, 2023)